Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Qiming Medical-B (02500.HK) by 23,000 shares on February 11, with a total net reduction of 111,500 shares over the past five trading days and 636,000 shares over the past twenty trading days [1] - As of now, southbound funds hold 52,088,100 shares of Qiming Medical-B, accounting for 11.8% of the company's total issued ordinary shares [1] Group 2 - Qiming Medical Co., Ltd. is primarily engaged in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices and auxiliary instruments for treating heart valve diseases [1] - The company's product line includes devices for interventional treatment of aortic valve, pulmonary valve, mitral valve, tricuspid valve diseases, as well as systems for radiofrequency ablation for hypertrophic cardiomyopathy and ultrasound ablation systems for renal denervation in hypertension [1] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolism protection device, with operations in both domestic and overseas markets [1]
启明医疗-B（02500.HK）：2月11日南向资金减持2.3万股